[Huahai Pharmaceutical Co., Ltd.: pemetrexed disodium for injection obtains Drug Registration Certificate] May 30, Huahai Pharmaceutical announced that the company recently received a drug registration certificate for pemetrexed disodium for injection approved and issued by the State Drug Administration. Pemetrexed disodium for injection is used in combination with cisplatin in the treatment of inoperable malignant pleural mesothelioma and in the treatment of non-small cell lung cancer. Huahai Pharmaceutical also announced that recently, the company declared to the United States FDA right amphetamine dimethylsulfonate capsule of the new drug brief application (ANDA, that is, the United States generic drug application) has been provisionally approved. Dextroamphetamine dimethanesulfonate capsule is mainly used in the treatment of attention deficit hyperactivity disorder.